RE:RE:RE:$Value to Insiders from a Potential BuyoutMy only gripe would be the evidence of countless early stage biotechs (ph 1) getting in the vicinity of $4-$5b. Onc may have been available for as little as $2-$2.5b with just the one indication (mBC). A purchase amount should be considerably higher after Goblet...but, I've never been through a biotech buyout, so who knows!?!